drugset / Trial / NCT01221792

Carvedilol Versus Placebo for Treatment in Post Traumatic Stress Disorder (PTSD)

NCT01221792

Phase 2 Unknown 80 enrolled Columbia Northwest Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The investigators hypothesize that carvedilol, at less then therapeutic doses for cardiac effect, will reduce symptoms of Post Traumatic Stress Disorder.

Timeline

Start
2010-10
Primary completion
2011-06
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Carvedilol Other / unclassified 6.25 mg Oral
Comparator Carvedilol Other / unclassified 15.625 mg Oral